Literature DB >> 31849187

The obesity paradox for outcomes in atrial fibrillation: Evidence from an exposure-effect analysis of prospective studies.

Xiao Liu1, Linjuan Guo1, Kaiwen Xiao2, Wengen Zhu1, Menglu Liu1, Rong Wan3, Kui Hong1,3.   

Abstract

The impact of obesity on the prognosis of atrial fibrillation (AF) remains controversial. We conducted an exposure-effect meta-analysis of prospective studies to clarify the relationship between body mass index (BMI) and outcomes in patients with AF. The Cochrane Library, PubMed, and Embase databases were searched through May 1, 2019. Summary relative risks (RRs) were calculated using random-effects models. Nonlinear associations were explored using restricted cubic spline models. Twenty publications involving 161,922 individuals were included. Categorical variable analysis showed that underweight was associated with an increased risk of all-cause mortality (RR: 2.6), cardiovascular death (RR: 2.91), major bleeding (RR: 1.57), stroke or systemic embolism (RR: 1.62), and a composite endpoint (RR: 2.23). In exposure-effect analysis, the risk per 5 BMI increase was reduced for adverse outcomes (RR=0.86, 95% CI: 0.80-0.92 for all-cause death; RR=0.82, 95% CI: 0.71-0.95 for cardiovascular death; RR=0.89, 95% CI: 0.84-0.95 for stroke or systemic embolism; and RR=0.78, 95% CI: 0.67-0.92 for a composite endpoint). There was a significant "U"-shaped exposure-effect relationship with all-cause death, and the nadir of the curve was observed at a BMI of approximately 28. Our results showed that underweight is associated with a worse prognosis, but that overweight and obesity are associated with improved adverse outcomes in patients with AF.
© 2019 World Obesity Federation.

Entities:  

Keywords:  atrial fibrillation; body mass index; meta-analysis; obesity paradox

Mesh:

Year:  2019        PMID: 31849187     DOI: 10.1111/obr.12970

Source DB:  PubMed          Journal:  Obes Rev        ISSN: 1467-7881            Impact factor:   9.213


  14 in total

Review 1.  Apixaban Use in Obese Patients: A Review of the Pharmacokinetic, Interventional, and Observational Study Data.

Authors:  Michael J Jamieson; Wonkyung Byon; Richard W Dettloff; Matthew Crawford; Peter S Gargalovic; Samira J Merali; Joelle Onorato; Andres J Quintero; Cristina Russ
Journal:  Am J Cardiovasc Drugs       Date:  2022-05-16       Impact factor: 3.571

2.  Development and Validation of a Novel Prognostic Model Predicting the Atrial Fibrillation Recurrence Risk for Persistent Atrial Fibrillation Patients Treated with Nifekalant During the First Radiofrequency Catheter Ablation.

Authors:  Youzheng Dong; Zhenyu Zhai; Bo Zhu; Shucai Xiao; Yang Chen; Anxue Hou; Pengtao Zou; Zirong Xia; Jianhua Yu; Juxiang Li
Journal:  Cardiovasc Drugs Ther       Date:  2022-06-22       Impact factor: 3.727

Review 3.  Relationship between the triglyceride-glucose index and risk of cardiovascular diseases and mortality in the general population: a systematic review and meta-analysis.

Authors:  Xiao Liu; Ziqi Tan; Yuna Huang; Huilei Zhao; Menglu Liu; Peng Yu; Jianyong Ma; Yujie Zhao; Wengen Zhu; Jingfeng Wang
Journal:  Cardiovasc Diabetol       Date:  2022-07-01       Impact factor: 8.949

4.  Association of Coffee Consumption With Atrial Fibrillation Risk: An Updated Dose-Response Meta-Analysis of Prospective Studies.

Authors:  Yalin Cao; Xiao Liu; Zhengbiao Xue; Kang Yin; Jianyong Ma; Wengen Zhu; Fuwei Liu; Jun Luo; Junyi Sun
Journal:  Front Cardiovasc Med       Date:  2022-07-06

5.  Independent effects of adiposity measures on risk of atrial fibrillation in men and women: a study of 0.5 million individuals.

Authors:  C Fielder Camm; Ben Lacey; M Sofia Massa; Adam Von Ende; Parag Gajendragadkar; Alexander Stiby; Elsa Valdes-Marquez; Sarah Lewington; Rohan Wijesurendra; Sarah Parish; Barbara Casadei; Jemma C Hopewell
Journal:  Int J Epidemiol       Date:  2022-06-13       Impact factor: 9.685

Review 6.  Impact of body mass index on procedural complications, procedure duration, and radiation dose in patients with atrial fibrillation undergoing radiofrequency ablation: A systematic review and meta-analysis.

Authors:  Menglu Liu; Kaibo Mei; Xiao Liu; Yujie Zhao
Journal:  Clin Cardiol       Date:  2020-06-03       Impact factor: 2.882

7.  Association of BMI, comorbidities and all-cause mortality by using a baseline mortality risk model.

Authors:  Jia Li; Gyorgy Simon; M Regina Castro; Vipin Kumar; Michael S Steinbach; Pedro J Caraballo
Journal:  PLoS One       Date:  2021-07-09       Impact factor: 3.752

8.  Dose-response analysis between hemoglobin A1c and risk of atrial fibrillation in patients with and without known diabetes.

Authors:  Huilei Zhao; Menglu Liu; Zhifeng Chen; Kaibo Mei; Peng Yu; Lixia Xie
Journal:  PLoS One       Date:  2020-02-18       Impact factor: 3.240

9.  LDL-C/HDL-C is associated with ischaemic stroke in patients with non-valvular atrial fibrillation: a case-control study.

Authors:  Xiao-Xue Zhang; Meng Wei; Lu-Xiang Shang; Yan-Mei Lu; Ling Zhang; Yao-Dong Li; Jiang-Hua Zhang; Qiang Xing; Zu Kela Tu-Erhong; Bao-Peng Tang; Xian-Hui Zhou
Journal:  Lipids Health Dis       Date:  2020-10-07       Impact factor: 3.876

Review 10.  Association of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers with risk of COVID-19, inflammation level, severity, and death in patients with COVID-19: A rapid systematic review and meta-analysis.

Authors:  Xiao Liu; Chuyan Long; Qinmei Xiong; Chen Chen; Jianyong Ma; Yuhao Su; Kui Hong
Journal:  Clin Cardiol       Date:  2020-08-05       Impact factor: 3.287

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.